Solexa — Lynx Therapeutics — Merger or Acquisition (February 2005)
23 slides from Solexa's merger presentation, Feb 22, 2005
Slide 1: Lynx / Solexa Merger: Dramatically Lowering the Cost of Whole Genome DNA Sequencing
Lynx / Solexa Merger Dramatically Lowering the Cost of Whole Genome DNA Sequencing
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains "forward-looking" statements, including statements related to the potential success under customer, collaboration and license arrangements, the expansion and success of Lynx's commercial applications of its genomics technologies, the proposed business
Slide 3: Other Information
Other Information Lynx filed an amended Registration Statement on Form S-4 (File No. 333-120101) with the SEC on January 21, 2005 and a final Proxy Statement/Prospectus on January 24, 2005 in connection with the proposed transaction with Solexa, and Lynx has mailed the Proxy Statement/Prospectus to
Slide 4: DNA Sequencing Overview
DNA Sequencing Overview Scientific / Technological One human genome = 3,000,000,000 "letters" (bases) Difference between humans is about 0.1% In 1982, biggest DNA sequence ever completed = 17,000 bases Over five orders of magnitude advance to human genome reference sequence (draft 2001, finished 200
Slide 5: Who We Are
Who We Are Lynx 1992 Spinout from Applied Biosystems Located in Hayward, CA (near San Francisco) About 75 employees Public (Nasdaq : LYNX) Solexa 1998 Spinout from Cambridge University Located in Little Chesterford, UK (near Cambridge) About 50 employees Private VC-backed company Merger expected fol
Slide 6: What Solexa Brings To The Merger
What Solexa Brings To The Merger Solexa pioneered single-molecule sequencing, using reversible terminators, starting in 1998. Novel chemistry platform Strong intellectual property position Experienced management Captive audience of first line customers World class investors - $40 million invested to
Slide 7: What Lynx Brings To The Merger
What Lynx Brings To The Merger Lynx pioneered bead-based sequencing, for gene expression, in the 1990's Established core group of customers Technology experts with molecular array instrument already a year into design Existing infrastructure supports service business US-based and US-listed
Slide 8: Lynx / Solexa Combination Enables Next Generation Technology
Merger builds critical mass to transform the market for DNA sequencing : Instruments, Reagents, Service, Software Initial products in 2005 50 - 100 x price / performance of current state-of-the-art technology This becomes the dominant business Lynx service business : Continue to build paying custome
Slide 9: Market Opportunity
Market Opportunity New product applications address large, established markets Research Market Market DNA Sequencing : > $ 700M Gene Expression : > $ 1 B Genotyping : > $ 300 M Customers Academic, government, non-profit, pharmaceutical & biotech labs Future Application - Genetic Diagnostics Low cost
Slide 10: Initial Sales Targets: Large DNA Sequencing Centers
Initial Sales Targets: Large DNA Sequencing Centers Large DNA sequencing centers continue to demand high volumes of genetic material sequencing Current sequencing costs are inhibitory to centers Desirable study sizes not feasible given current costs Government funding for genomic research continues
Slide 11: CEO Profile: John West
CEO Profile : John West Previously VP, DNA Platforms, Applied Biosystems $1.1B business Led the development & launch of the DNA sequencer currently used by every major genome center Formerly CEO, Princeton Instruments High-end low-light scientific imaging (incl single DNA molecules) 10x revenue grow
Slide 12: CTO Profile - Tony Smith
CTO Profile - Tony Smith With Solexa since January 2002 Previously VP, R & D - UK, Amersham Biosciences (now GE) 220 R & D staff Developing systems (H/W, S/W, reagents, applications) for leading Life Science Research Institutions, Pharma & Biotech 20 years experience in R & D and project management
Slide 13: Large improvements in performance and price
Large improvements in performance and price: ~100x higher spot density x ~100x more data per spot = Revolutionary price / performance potential Dramatically Higher Data Density
Slide 14: Molecular Array Technology
Molecular Array Technology 100x higher density than conventional arrays In conventional arrays the density, 10k - 1M / square cm, is set by mechanical or photolithographic spotting. With conventional re-sequencing arrays, four spots are needed to read just one base (so 1/4 base per spot) To re-seque
Slide 15: With Our DNA Sequencing Chemistry, We Add A Third Dimension
With Our DNA Sequencing Chemistry, We Add A Third Dimension GATCCTTCGGATCTAGTCGATCCAT... In molecular arrays the density, up to 100M / square cm, is set by the molecules themselves. With our biochemistry, we determine a sequence of at least 25 bases at each spot (> 100x more data per spot). This den
Slide 16: Cloned Single Molecule Arrays
Cloned Single Molecule Arrays(tm) provide an optimum combination of density and detection. The result will be higher throughput, lower cost and a faster path to market. Reagent cost of amplification is negligible. Greater Density More Sensitive Detection More Data at Significantly Lower Costs
Slide 17: Established Service Infrastructure
The Lynx service lab already has 30 instruments running 24 x 7. Established Service Infrastructure
Slide 18: Reversible Terminators: Accuracy and Efficiency
Reversible Terminators : Accuracy and Efficiency Critical to Whole Genome Analysis Without high-accuracy, whole genome experiments would be impractically constrained by false-positive "mutations". Our reversible terminator technology and custom engineered enzymes provide clean signals, required to m
Slide 19: Positioning
Positioning Relative to conventional sequencing 100x higher throughput & lower cost > 1,000x less sample prep up front Relative to array based re-sequencing 10 - 100x higher spot density >100x more sequence data per spot Relative to current genome-scale genotyping technologies Access potentially muc
Slide 20: Intellectual Property
Intellectual Property Over 50 US patents issued Over 100 more coming Priority dates from 1993 Our IP predates the incorporation of most of our competitors! Early IP in single molecule sequencing Particular focus on sequencing-by-synthesis Internal IP already bolstered by key IP acquisitions IP cover
Slide 21: Why Lynx / Solexa Will Win
Why Lynx / Solexa Will Win First to market with molecular arrays First arrays designed specifically for DNA sequencing Highest data density transforming cost and throughput Molecules define the array feature size 500x density vs competitor's bead-based systems Sequencing adds a third dimension Compr
Slide 22: Next Month Milestones
Next 18 Month Milestones S-4 effective late-January Merger completion in early-March Financing post-merger, $20 - 35M, led by insiders Sequencing of increasing scale: Viruses Bacteria Human chromosomes Whole human Transition service customers to combination technology Beta testing system in Q4 05 Ta
Slide 23: Lynx / Solexa Merger: Dramatically Lowering the Cost of Whole Genome DNA Sequencing
Lynx / Solexa Merger Dramatically Lowering the Cost of Whole Genome DNA Sequencing
Lynx Therapeutics — Merger or Acquisition (February 2005) on 6ix